Teva Stops Production At US Plant After FDA Concerns: Report

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) has temporarily stopped drug production at its Irvine plant in California to address issues raised by the FDA after a recent inspection.
The Company did not specify the issues raised by the agency.
Bloomberg reported that the production halt followed Teva's recall of more than 2.5 million vials of drugs in recent months, many of them cancer medications.
The report said the vials might have been contaminated with mold owing to water leaks discovered by FDA inspectors.
Teva said the plant received an FDA Form 483, which lists observations of issues leading to potential FDA rule violations.
"We have carefully reviewed the 483 and are taking extensive actions to ensure the agency's observations are fully addressed," Teva told Reuters.
Related: Teva Recalls One Batch Of Topotecan After Complaint Of Glass Particulate In Vial.
Price Action: TEVA stock is down 1.19% at $9.58 during the market session on the last check Monday.